People
The People
Governance grade: B. Sarah London inherited a company in crisis after founder Michael Neidorff's death in November 2022 and has stabilized operations, cut SG&A by 110bp, and begun portfolio rationalization (Magellan divestitures). The main concern is thin insider ownership relative to company size and the aggressive buyback program that continued through margin deterioration. The board is refreshed and independent but lacks deep managed care operating experience.
The People Running This Company
Sarah London took over after Neidorff's death, becoming CEO at 39 — young for a $100B+ revenue company. Her track record: stabilized the company through the Medicaid redetermination wave, drove SG&A from 8.5% to 7.4%, divested non-core assets (Circle Health, Magellan Rx, Magellan Specialty Health, CHS), and repriced 95% of Marketplace business in Q3 2025 when utilization spiked. The Q1 FY2026 earnings beat and guidance raise validate her operational credibility.
The April 2026 leadership restructure — hiring Dan Finke (former Aetna President) for Medicaid/Commercial and elevating Michael Carson for Medicare/Specialty — signals a shift from crisis management to growth execution.
What They Get Paid
London's $20.6M total compensation (per external data) is reasonable for a Fortune 25 company CEO — UNH's Andrew Witty earned $23.5M in his final year. The 93% equity weighting creates alignment, though the performance conditions on London's options (stock must close at or above $100 for 20 consecutive trading days) are currently deeply out of the money at $53.69. This creates a strong incentive to drive stock recovery but also raises questions about whether management might take excessive risk.
The 2022 proxy introduced adjusted net earnings margin metrics to align management incentives with the margin expansion strategy — an appropriate response to stockholder feedback.
Are They Aligned?
CEO London's August 2025 open-market purchase at $25.50 — buying 19,230 shares near the 52-week low of $25.21 — is the most meaningful insider signal. She put personal capital at risk when the stock was at its nadir following the goodwill impairment announcement. The stock has since doubled to $53.69.
The buyback program deserves scrutiny: $7.9B in FY2022-2024 was funded partly by operating cash flow and partly by maintaining high debt levels. In hindsight, buying back stock at $70-80 while the business faced margin pressure was aggressive. Management corrected in FY2026 by suspending buybacks entirely and directing cash to debt reduction ($1.9B repaid in FY2025).
Skin-in-the-game score: 6/10. London's direct ownership is thin (0.052%), but the open-market buy, heavy equity compensation weighting, and buyback suspension at the right time show rational capital allocation instincts.
Board Quality
The board was substantially refreshed in 2021-2022 — six of nine directors joined within two years, addressing governance concerns from the Neidorff era. Gender and ethnic diversity reached 43%. Chairman Eppinger (Stewart Information Services CEO) brings insurance industry perspective.
Strengths: High independence (8 of 9 independent), recent refreshment eliminates founder-era entrenchment, audit committee led by former Deloitte Vice Chairman (Blume), strong financial expertise (two former Fortune 500 CFOs).
Weaknesses: Only Burdick has direct managed care operating experience (former WellCare CEO). No current hospital system executive or physician on the board for a company managing healthcare for 28M people. Two technology-focused directors (Dallas, Ford) but unclear how their expertise translates to managed care operations.
The Verdict
Grade: B. London has proven capable under fire — navigating the post-Neidorff transition, Medicaid redeterminations, the goodwill impairment, and multiple divestitures. The Q1 FY2026 beat and raised guidance are tangible evidence of execution. The board is refreshed, independent, and competent but could use more managed care depth.
Strongest positives: CEO open-market buy at the low, SG&A discipline (7.4% ratio), rational buyback suspension in FY2026, clean leadership restructure with experienced hires (Finke from CVS/Aetna).
Real concerns: thin direct CEO ownership, $7.9B in buybacks during FY2022-2024 when margins were under pressure looks like poor timing, and the board lacks deep managed care expertise beyond Burdick.
What would upgrade the grade: London or other executives making additional open-market purchases above $50, successful Magellan divestiture closing at reasonable terms, and Medicaid HBR improving to under 92% for two consecutive quarters.